. "0954-691X" . . . "%22Efficacy and safety of peginterferon \u03B1-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe"@en . "Urb\u00E1nek, Petr" . . . "7"^^ . "23" . . "11" . . . . "7"^^ . . "Messinger, D." . . "All patients in this open-label multinational study were assigned at the investigator'sdiscretion to receive peginterferon \u03B1-2a (40 KD) 180 \u00B5g/week plus ribavirin (800 mg/day) for a total of 24 weeks or peginterferon \u03B1-2a (40 KD) 180 \u00B5g/week plus ribavirin (1000/1200 mg/day) for a total of 48 weeks. Treatment success was defined as sustained virological response [sustained virological response (SVR); hepatitis C virus RNA less than 50 IU/ml after completion of untreated follow-up]. The combination of peginterferon \u03B1-2a (40 KD) plus ribavirin was well tolerated and produced an overall SVR rate of 58% in treatment-naive patients. This study confirms that SVR rates achieved in pivotal clinical trials in Western Europe and the USA can be achieved in routine clinical practice in Central and Eastern Europe."@en . . "RIV/61383082:_____/11:0070!RIV12-MO0-61383082" . "RIV/61383082:_____/11:0070" . "196704" . . "European journal of gastroenterology & hepatology 2011" . . "Ivanovski, L." . "%22Efficacy and safety of peginterferon \u03B1-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe" . "Oltman, M." . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "Hepatitis C; pegylated interferon; ribavirin; sustained virological response"@en . "All patients in this open-label multinational study were assigned at the investigator'sdiscretion to receive peginterferon \u03B1-2a (40 KD) 180 \u00B5g/week plus ribavirin (800 mg/day) for a total of 24 weeks or peginterferon \u03B1-2a (40 KD) 180 \u00B5g/week plus ribavirin (1000/1200 mg/day) for a total of 48 weeks. Treatment success was defined as sustained virological response [sustained virological response (SVR); hepatitis C virus RNA less than 50 IU/ml after completion of untreated follow-up]. The combination of peginterferon \u03B1-2a (40 KD) plus ribavirin was well tolerated and produced an overall SVR rate of 58% in treatment-naive patients. This study confirms that SVR rates achieved in pivotal clinical trials in Western Europe and the USA can be achieved in routine clinical practice in Central and Eastern Europe." . . . . "Reh\u00E1k, V." . "%22Efficacy and safety of peginterferon \u03B1-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe"@en . "Husa, P." . "S, V" . "%22Efficacy and safety of peginterferon \u03B1-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe" . "[0E0BF2B37CC3]" . "1"^^ . "10.1097/MEG.0b013e32834b326b" . "Tietz, A." .